27.11.2006
For the second year running the university sponsored the University Enterprise Award at the Sussex Business Awards. The award went to Allergy Therapeutics Plc, a specialist pharmaceutical company which has the potential to transform allergy treatment.
The company aims to provide novel therapies for the prevention and treatment of allergy. It does this with a range of innovative, patent protected, high-value, allergy vaccines.
Allergy Therapeutics, established in 1998, has 275 employees and is based in Worthing. It is now looking to expand in Europe, both organically and via acquisitions.
Andrew Toal (left), Head of Business Services at the University of Brighton, with Bev Lees and Murray Skinner from Allergy Therapeutics Plc.
Over the past five years Allergy Therapeutics has developed a special relationship with the School of Pharmacy and Biomolecular Sciences. This collaboration, which has involved multiple fixed term contracts, including a knowledge transfer partnership (KTP), funded in part by the department of trade and industry, has been integral to the company's corporate mission.
Colin Monk said: "The university has a long history of working in partnership with businesses for the benefit of the region. We have worked successfully with Allergy Therapeutics on KTPs and look forward to a sustained relationship."
Contact: Marketing and Communications, University of Brighton, 01273 643022
